58584-60-4

Usage

Uses

Used in Pharmaceutical Industry:
(2-amino-6-chloro-pyridin-3-yl)-methanol is used as a building block for the synthesis of various functionalized pyridine derivatives. Its presence of chloro and amino groups makes it a versatile compound for creating pharmaceutical intermediates with potential applications in drug development and medicinal chemistry.
Used in Drug Development:
(2-amino-6-chloro-pyridin-3-yl)-methanol is used as a starting material for the development of new drugs. Its unique structure and functional groups allow for the creation of novel compounds with potential therapeutic properties.
Used in Medicinal Chemistry:
(2-amino-6-chloro-pyridin-3-yl)-methanol is used as a research compound in medicinal chemistry to explore its potential pharmacological properties and its role in the synthesis of new pharmaceutical agents.

Upstream product

• 55304-90-0 2,6-dichloro-3-(hydroxymethyl)pyridine 
• 2402-78-0 2,6-dichloropyridine 
• 58584-92-2 2-amino-6-chloronicotinic acid 
• 873936-99-3 2-amino-6-chloro-N-methoxy-N-methylnicotinamide 
• 38496-18-3 2,6-dichloropyridine-3-carboxylic acid 
• 55304-73-9 2,6-dichloro-pyridine-3-carbaldehyde 

Downstream Products

• 58584-61-5 2-amino-6-chloropyridine-3-carbaldehyde 

Relevant academic research and scientific papers

1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF

1,8-naphthyridinone compounds as modulators of an adenosine receptor are provided. The compounds may find use as therapeutic agents for the treatment of diseases mediated through a G-protein-coupled receptor signaling pathway and may find particular use in oncology.

CHEMICAL COMPOUNDS AS H-PGDS INHIBITORS

A compound of formula (I) wherein R1, R2, R3, R4, X, Y, and A are as defined herein. The compounds of the present invention are inhibitors of hematopoietic prostaglandin D synthase (H-PGDS) and can be useful in the treatment of Duchenne muscular dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

BENZOXAZINONE DERIVATIVES AND ANALOGUES THEREOF AS MODULATORS OF TNF ACTIVITY

A series of substituted 3,4-dihydro-2H-.1,4-benzoxazin-3-one derivatives, and analogues thereof, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune

Synthesis, in vitro and in vivo activity of thiamine antagonist transketolase inhibitors

Tumor cells extensively utilize the pentose phosphate pathway for the synthesis of ribose. Transketolase is a key enzyme in this pathway and has been suggested as a target for inhibition in the treatment of cancer. In a pharmacodynamic study, nude mice with xenografted HCT-116 tumors were dosed with 1 ('N3′-pyridyl thiamine'; 3-(6-methyl-2-amino-pyridin-3-ylmethyl)-5-(2-hydroxy-ethyl)-4-methyl-thiazol-3-ium chloride hydrochloride), an analog of thiamine, the co-factor of transketolase. Transketolase activity was almost completely suppressed in blood, spleen, and tumor cells, but there was little effect on the activity of the other thiamine-utilizing enzymes α-ketoglutarate dehydrogenase or glucose-6-phosphate dehydrogenase. Synthesis and SAR of transketolase inhibitors is described.

Novel 1,4-benzodiazepine-2,5-diones as Hdm2 antagonists with improved cellular activity

The disruption of the p53-Hdm2 protein-protein interaction induces cell growth arrest and apoptosis. We have identified the 1,4-benzodiazepine-2,5-dione scaffold as a suitable template for inhibiting this interaction by binding to the Hdm2 protein. Several compounds have been made with improved potency, solubility, and cell-based activities.